273 related articles for article (PubMed ID: 34479925)
1. Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer.
DeMaria PJ; Lee-Wisdom K; Donahue RN; Madan RA; Karzai F; Schwab A; Palena C; Jochems C; Floudas C; Strauss J; Marté JL; Redman JM; Dombi E; Widemann B; Korchin B; Adams T; Pico-Navarro C; Heery C; Schlom J; Gulley JL; Bilusic M
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34479925
[TBL] [Abstract][Full Text] [Related]
2. Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury.
Heery CR; Palena C; McMahon S; Donahue RN; Lepone LM; Grenga I; Dirmeier U; Cordes L; Marté J; Dahut W; Singh H; Madan RA; Fernando RI; Hamilton DH; Schlom J; Gulley JL
Clin Cancer Res; 2017 Nov; 23(22):6833-6845. PubMed ID: 28855356
[No Abstract] [Full Text] [Related]
3. Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC).
Bilusic M; McMahon S; Madan RA; Karzai F; Tsai YT; Donahue RN; Palena C; Jochems C; Marté JL; Floudas C; Strauss J; Redman J; Abdul Sater H; Rabizadeh S; Soon-Shiong P; Schlom J; Gulley JL
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762322
[TBL] [Abstract][Full Text] [Related]
4. Phase I Trial of a Modified Vaccinia Ankara Priming Vaccine Followed by a Fowlpox Virus Boosting Vaccine Modified to Express Brachyury and Costimulatory Molecules in Advanced Solid Tumors.
Collins JM; Donahue RN; Tsai YT; Manu M; Palena C; Gatti-Mays ME; Marté JL; Madan RA; Karzai F; Heery CR; Strauss J; Abdul-Sater H; Cordes L; Schlom J; Gulley JL; Bilusic M
Oncologist; 2020 Jul; 25(7):560-e1006. PubMed ID: 31876334
[TBL] [Abstract][Full Text] [Related]
5. Randomized, Double-Blind, Placebo-Controlled Phase II Study of Yeast-Brachyury Vaccine (GI-6301) in Combination with Standard-of-Care Radiotherapy in Locally Advanced, Unresectable Chordoma.
DeMaria PJ; Bilusic M; Park DM; Heery CR; Donahue RN; Madan RA; Bagheri MH; Strauss J; Shen V; Marté JL; Steinberg SM; Schlom J; Gilbert MR; Gulley JL
Oncologist; 2021 May; 26(5):e847-e858. PubMed ID: 33594772
[TBL] [Abstract][Full Text] [Related]
6. Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury.
Heery CR; Singh BH; Rauckhorst M; Marté JL; Donahue RN; Grenga I; Rodell TC; Dahut W; Arlen PM; Madan RA; Schlom J; Gulley JL
Cancer Immunol Res; 2015 Nov; 3(11):1248-56. PubMed ID: 26130065
[TBL] [Abstract][Full Text] [Related]
7. A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer.
Gatti-Mays ME; Redman JM; Donahue RN; Palena C; Madan RA; Karzai F; Bilusic M; Sater HA; Marté JL; Cordes LM; McMahon S; Steinberg SM; Orpia A; Burmeister A; Schlom J; Gulley JL; Strauss J
Oncologist; 2020 Jun; 25(6):479-e899. PubMed ID: 31594913
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
[TBL] [Abstract][Full Text] [Related]
9. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.
Heery CR; O'Sullivan-Coyne G; Madan RA; Cordes L; Rajan A; Rauckhorst M; Lamping E; Oyelakin I; Marté JL; Lepone LM; Donahue RN; Grenga I; Cuillerot JM; Neuteboom B; Heydebreck AV; Chin K; Schlom J; Gulley JL
Lancet Oncol; 2017 May; 18(5):587-598. PubMed ID: 28373007
[TBL] [Abstract][Full Text] [Related]
10. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
[TBL] [Abstract][Full Text] [Related]
11. A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules.
Gatti-Mays ME; Strauss J; Donahue RN; Palena C; Del Rivero J; Redman JM; Madan RA; Marté JL; Cordes LM; Lamping E; Orpia A; Burmeister A; Wagner E; Pico Navarro C; Heery CR; Schlom J; Gulley JL
Clin Cancer Res; 2019 Aug; 25(16):4933-4944. PubMed ID: 31110074
[TBL] [Abstract][Full Text] [Related]
12. Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial.
Milligan ID; Gibani MM; Sewell R; Clutterbuck EA; Campbell D; Plested E; Nuthall E; Voysey M; Silva-Reyes L; McElrath MJ; De Rosa SC; Frahm N; Cohen KW; Shukarev G; Orzabal N; van Duijnhoven W; Truyers C; Bachmayer N; Splinter D; Samy N; Pau MG; Schuitemaker H; Luhn K; Callendret B; Van Hoof J; Douoguih M; Ewer K; Angus B; Pollard AJ; Snape MD
JAMA; 2016 Apr; 315(15):1610-23. PubMed ID: 27092831
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Subcutaneous vs Intravenous Administration of Anti-PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors: A Phase 1 Dose-Escalation Trial.
Johnson ML; Braiteh F; Grilley-Olson JE; Chou J; Davda J; Forgie A; Li R; Jacobs I; Kazazi F; Hu-Lieskovan S
JAMA Oncol; 2019 Jul; 5(7):999-1007. PubMed ID: 31145415
[TBL] [Abstract][Full Text] [Related]
14. Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer.
Redman JM; Steinberg SM; Gulley JL
J Immunother Cancer; 2018 Sep; 6(1):91. PubMed ID: 30227893
[TBL] [Abstract][Full Text] [Related]
15. Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer.
Gatti-Mays ME; Gameiro SR; Ozawa Y; Knudson KM; Hicks KC; Palena C; Cordes LM; Steinberg SM; Francis D; Karzai F; Lipkowitz S; Donahue RN; Jochems C; Schlom J; Gulley JL
Front Oncol; 2020; 10():581801. PubMed ID: 33747894
[TBL] [Abstract][Full Text] [Related]
16. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
Madan RA; Mohebtash M; Arlen PM; Vergati M; Rauckhorst M; Steinberg SM; Tsang KY; Poole DJ; Parnes HL; Wright JJ; Dahut WL; Schlom J; Gulley JL
Lancet Oncol; 2012 May; 13(5):501-8. PubMed ID: 22326924
[TBL] [Abstract][Full Text] [Related]
17. Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine.
Hamilton DH; Litzinger MT; Jales A; Huang B; Fernando RI; Hodge JW; Ardiani A; Apelian D; Schlom J; Palena C
Oncotarget; 2013 Oct; 4(10):1777-90. PubMed ID: 24125763
[TBL] [Abstract][Full Text] [Related]
18. Clinical evaluation of TRICOM vector therapeutic cancer vaccines.
Madan RA; Bilusic M; Heery C; Schlom J; Gulley JL
Semin Oncol; 2012 Jun; 39(3):296-304. PubMed ID: 22595052
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-α-2b in patients with CEA-expressing carcinomas.
Duggan MC; Jochems C; Donahue RN; Richards J; Karpa V; Foust E; Paul B; Brooks T; Tridandapani S; Olencki T; Pan X; Lesinski GB; Schlom J; Carson Iii WE
Cancer Immunol Immunother; 2016 Nov; 65(11):1353-1364. PubMed ID: 27581603
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.
Marshall JL; Gulley JL; Arlen PM; Beetham PK; Tsang KY; Slack R; Hodge JW; Doren S; Grosenbach DW; Hwang J; Fox E; Odogwu L; Park S; Panicali D; Schlom J
J Clin Oncol; 2005 Feb; 23(4):720-31. PubMed ID: 15613691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
